BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33608002)

  • 1. Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort.
    Lejeune S; Roy C; Slimani A; Pasquet A; Vancraeynest D; Vanoverschelde JL; Gerber BL; Beauloye C; Pouleur AC
    Cardiovasc Diabetol; 2021 Feb; 20(1):48. PubMed ID: 33608002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus.
    Jang SY; Jang J; Yang DH; Cho HJ; Lim S; Jeon ES; Lee SE; Kim JJ; Kang SM; Baek SH; Cho MC; Choi DJ; Yoo BS; Kim KH; Park SK; Lee HY
    Cardiovasc Diabetol; 2021 Sep; 20(1):180. PubMed ID: 34496864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: insight from ventricular remodeling using cardiac MRI.
    Shi K; Zhang G; Fu H; Li XM; Gao Y; Shi R; Xu HY; Li Y; Guo YK; Yang ZG
    Cardiovasc Diabetol; 2024 Apr; 23(1):148. PubMed ID: 38685007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction.
    Roy C; Slimani A; de Meester C; Amzulescu M; Pasquet A; Vancraeynest D; Beauloye C; Vanoverschelde JL; Gerber BL; Pouleur AC
    J Cardiovasc Magn Reson; 2018 Aug; 20(1):55. PubMed ID: 30086783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction.
    Menghoum N; Badii MC; Deltombe M; Lejeune S; Roy C; Vancraeynest D; Pasquet A; Gerber BL; Horman S; Gruson D; Beauloye C; Pouleur AC
    ESC Heart Fail; 2024 Jun; 11(3):1493-1505. PubMed ID: 38339764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
    Lindman BR; Dávila-Román VG; Mann DL; McNulty S; Semigran MJ; Lewis GD; de las Fuentes L; Joseph SM; Vader J; Hernandez AF; Redfield MM
    J Am Coll Cardiol; 2014 Aug; 64(6):541-9. PubMed ID: 25104521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic importance of comorbidities in heart failure with preserved left ventricular ejection fraction.
    Maréchaux S; Six-Carpentier MM; Bouabdallaoui N; Montaigne D; Bauchart JJ; Mouquet F; Auffray JL; Le Tourneau T; Asseman P; LeJemtel TH; Ennezat PV
    Heart Vessels; 2011 May; 26(3):313-20. PubMed ID: 21063875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic control is a predictor of infection-related hospitalization on haemodialysis patients: Miyazaki Dialysis Cohort study (MID study).
    Toida T; Sato Y; Nakagawa H; Komatsu H; Kikuchi M; Uezono S; Yamada K; Ishihara T; Hisanaga S; Kitamura K; Fujimoto S
    Nephrology (Carlton); 2016 Mar; 21(3):236-40. PubMed ID: 26272229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
    Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic Markers and Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Echouffo-Tcheugui JB; Ogunmoroti O; Golden SH; Bertoni AG; Mongraw-Chaffin M; Pandey A; Ndumele CE; Michos ED
    J Card Fail; 2022 Nov; 28(11):1593-1603. PubMed ID: 35114382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5-Year CORONOR Registry.
    Lemesle G; Meurice T; Tricot O; Lamblin N; Bauters C
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29728374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart Failure with Normal Natriuretic Peptide Levels and Preserved Ejection Fraction: A Prospective Clinical and Cardiac MRI Study.
    He J; Yang W; Wu W; Yin G; Zhuang B; Xu J; Zhou D; Zhang J; Wang Y; Zhu L; Sun X; Sirajuddin A; Teng Z; Kureshi F; Arai AE; Zhao S; Lu M
    Radiol Cardiothorac Imaging; 2024 Jun; 6(3):e230281. PubMed ID: 38695743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.
    Sanders-van Wijk S; van Empel V; Davarzani N; Maeder MT; Handschin R; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2015 Oct; 17(10):1006-14. PubMed ID: 26472682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study.
    Donal E; Lund LH; Oger E; Hage C; Persson H; Reynaud A; Ennezat PV; Bauer F; Drouet E; Linde C; Daubert C;
    Eur J Heart Fail; 2015 Jul; 17(7):680-8. PubMed ID: 26033771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease.
    Marcun R; Stankovic I; Vidakovic R; Farkas J; Kadivec S; Putnikovic B; Ilic I; Neskovic AN; Lainscak M
    Intern Emerg Med; 2016 Jun; 11(4):519-27. PubMed ID: 26423072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
    Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
    Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction.
    Selvaraj S; Ilkhanoff L; Burke MA; Freed BH; Lang RM; Martinez EE; Shah SJ
    J Am Soc Echocardiogr; 2014 Jan; 27(1):74-82.e2. PubMed ID: 24075945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.